Deucravacitinib Shows Promising Long-Term Efficacy in Psoriasis Treatment Across Age Groups, BMI Variations
A recent study led by Teppei Hagino and his team at Nippon Medical School Chiba Hokusoh Hospital in Japan has shed new light on the long-term effectiveness of deucravacitinib, a groundbreaking treatment for moderate-to-severe psoriasis. The findings, published in the Journal of Dermatology, reveal that the drug is effective across different age groups, though its responsiveness may vary slightly based on body mass index (BMI).
The Study’s Objective and Design
The research aimed to evaluate the 52-week real-world effectiveness of deucravacitinib in psoriasis patients,stratified by age and BMI. Conducted between December 2022 and August 2024, the study included patients aged 15 years or older with clinical diagnoses of moderate-to-severe psoriasis. Participants with conditions such as psoriatic arthritis (PsA), psoriasis vulgaris, and erythrodermic psoriasis were also included.
Notably, patients who had recently used systemic therapies were switched to deucravacitinib without a washout period. this meant that pre-treatment Psoriasis area and Severity index (PASI) scores from their previous medications were not consistently available. As a result, the researchers used PASI scores at the time of the switch as baseline values. Participants received a daily oral dose of 6 mg of deucravacitinib for up to 52 weeks.
The study meticulously assessed baseline characteristics, including BMI, age, sex, and clinical features such as prior treatment with apremilast or biologics, duration of psoriasis, and involvement of specific areas like the nails, scalp, or genital region. comorbidities such as diabetes and cardiovascular disease were also evaluated, alongside smoking status and baseline static Physician’s Global Assessment (sPGA) and Dermatology Life Quality Index (DLQI) scores.
Key Findings: Age and BMI impact
At the 52-week mark, the study revealed significant insights into the drug’s effectiveness across different demographics. Among patients aged 65 years or older, the rates of achieving PASI 75, PASI 90, and PASI 100 were 86.36%, 59.09%, and 13.64%,respectively.In comparison, younger patients (<65 years) showed rates of 86.36%, 65.22%, and 39.13%, respectively. While the PASI 75 and PASI 90 rates were comparable across age groups, the PASI 100 rate was notably lower in older patients. This suggests that while deucravacitinib remains effective for elderly patients, younger individuals may experiance slightly better outcomes in achieving complete clearance of psoriasis symptoms.
The study also highlighted differences based on BMI. Patients with a BMI ≥25 achieved PASI 75, PASI 90, and PASI 100 rates of 81.82%, 73.33%, and 18.18%,respectively. In contrast, those with a BMI <25 showed rates of 90.91%, 80.00%, and 40.00%. These findings indicate that while deucravacitinib is effective across BMI categories, patients with a lower BMI may experience marginally better treatment responsiveness.
Implications for Personalized Psoriasis Treatment
“the present results indicate that deucravacitinib may be effective for elderly psoriasis patients and also younger or middle-aged patients, while treatment responsiveness in patients with a BMI ≥25 may be slightly lower compared with those with a BMI <25,” the researchers concluded. This study underscores the importance of personalized treatment strategies in managing psoriasis, a chronic condition that affects millions worldwide. By understanding how factors like age and BMI influence treatment outcomes, dermatologists can better tailor therapies to individual patient needs.
Summary of Key Findings
| Category | PASI 75 | PASI 90 | PASI 100 |
|———————–|————-|————-|————–|
| Age ≥65 | 86.36% | 59.09% | 13.64% |
| Age <65 | 86.36% | 65.22% | 39.13% |
| BMI ≥25 | 81.82% | 73.33% | 18.18% |
| BMI <25 | 90.91% | 80.00% | 40.00% |
The findings from this study provide valuable insights into the long-term effectiveness of deucravacitinib, offering hope for patients and clinicians alike in the ongoing battle against psoriasis. For more facts on deucravacitinib and its uses, visit Drugs.com.
Deucravacitinib: A Breakthrough in Psoriasis Treatment Across Age and BMI Groups
in a groundbreaking study led by Teppei Hagino and his team at Nippon Medical School Chiba hokusoh Hospital in Japan,the long-term efficacy of deucravacitinib in treating moderate-to-severe psoriasis has been meticulously evaluated. Published in the Journal of Dermatology, the research highlights the drug’s effectiveness across various age groups and its nuanced responsiveness based on body mass index (BMI). To delve deeper into these findings, we sat down with Dr. Emily Carter, a renowned dermatologist and psoriasis expert, for an insightful discussion.
The study’s Objective and design
Senior Editor: Dr. Carter, thank you for joining us today. Could you start by explaining the primary objective of this study and how it was structured?
Dr. Emily Carter: absolutely. The study aimed to assess the 52-week real-world effectiveness of deucravacitinib in patients with moderate-to-severe psoriasis, focusing on differences based on age and BMI.Conducted between december 2022 and August 2024, it included patients aged 15 and older, encompassing various clinical presentations such as psoriatic arthritis (PsA), psoriasis vulgaris, and erythrodermic psoriasis. importantly, participants were switched to deucravacitinib from other systemic therapies without a washout period, meaning baseline PASI scores were taken at the time of the switch. They received a daily oral dose of 6 mg for up to 52 weeks, and extensive data on demographics, clinical features, and comorbidities were collected.
Key Findings: Age and BMI Impact
Senior Editor: What were the most significant findings regarding age and BMI in this study?
Dr. Emily Carter: The data revealed interesting insights. For patients aged 65 and older, the rates of achieving PASI 75, PASI 90, and PASI 100 were 86.36%, 59.09%, and 13.64%, respectively.In contrast, younger patients (<65 years) showed rates of 86.36%,65.22%, and 39.13%. While the PASI 75 and PASI 90 rates were comparable across age groups, the PASI 100 rate was notably lower in older patients, suggesting slightly better complete clearance in younger individuals. Additionally, BMI played a role: patients with a BMI ≥25 achieved PASI 75, PASI 90, and PASI 100 rates of 81.82%,73.33%, and 18.18%, while those with a BMI <25 showed rates of 90.91%, 80.00%,and 40.00%. This indicates that while deucravacitinib remains effective across BMI categories, patients with a lower BMI may experience marginally better outcomes.
Implications for Personalized Psoriasis Treatment
Senior Editor: How do these findings influence the way dermatologists approach personalized treatment for psoriasis?
Dr. Emily Carter: These results are incredibly valuable for tailoring treatment strategies. As a notable example, the study confirms that deucravacitinib is effective for elderly patients, which is crucial given the challenges of managing psoriasis in older populations. However, the slightly lower PASI 100 rates in this group suggest that clinicians may need to consider additional interventions or adjust expectations. Similarly, the BMI-related variations highlight the importance of considering a patient’s weight when prescribing treatments.By understanding these nuances,dermatologists can optimize therapy for individual needs,improving both efficacy and patient satisfaction.
Summary of Key Findings
Here’s a fast summary of the study’s key findings:
| Category | PASI 75 | PASI 90 | PASI 100 |
|---|---|---|---|
| Age ≥65 | 86.36% | 59.09% | 13.64% |
| Age <65 | 86.36% | 65.22% | 39.13% |
| BMI ≥25 | 81.82% | 73.33% | 18.18% |
| BMI <25 | 90.91% | 80.00% | 40.00% |
Conclusion
Senior Editor: Dr. Carter,thank you for sharing your expertise. To wrap up, what would you say are the main takeaways from this study for both clinicians and patients?
Dr. Emily Carter: This study underscores the potential of deucravacitinib as a highly effective long-term treatment for moderate-to-severe psoriasis, nonetheless of age or BMI. However, it also highlights the importance of individualized treatment plans, considering factors like age and weight to maximize outcomes. For patients, this offers hope for better management of their symptoms, and for clinicians, it provides a roadmap for more personalized care. It’s an exciting step forward in the fight against psoriasis.
